Share price · BMY
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BMY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 12 Oct 2026-2.6%
Nothing announced by BMY that day or the session before.
- 5 Oct 2026-3.8%
Nothing announced by BMY that day or the session before.
- 5 Aug 2026-3.4%
Nothing announced by BMY that day or the session before.
- 30 Jul 2026+2.8%
- 15 Jul 2026+3.1%
Nothing announced by BMY that day or the session before.
- 13 Jul 2026+3.1%
- 1 Jul 2026-2.0%
Nothing announced by BMY that day or the session before.
- 8 Jun 2026-3.0%
Nothing announced by BMY that day or the session before.
- 1 Jun 2026-3.9%
- Day beforeCorcept Therapeutics: SYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid MalignanciesCORT +1.4%
- 1 May 2026-3.9%
Share of unusual movement by asset
For each asset, the share of BMY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(61 total)
| Target & Modality | |||
|---|---|---|---|
Abatacept(Orencia) | Approved | CD80/CD86 (CTLA-4-Ig) · Selective T Cell Costimulation Modulator · CD80/CD86 (B7-1/B7-2) on antigen-presenting cellsProtein / enzyme therapeutic | Psoriatic ArthritisRheumatoid Arthritis |
Adagrasib(Krazati) | Approved | KRAS G12CSmall molecule | Non-Small Cell Lung Cancer |
| Approved | DNMT1 (DNA methyltransferase 1)Small molecule | Acute Myeloid LeukemiaMyelodysplastic Syndromes | |
| Approved | DNMT1 (DNA methyltransferase 1)Small molecule | Acute Myeloid Leukemia | |
deucravacitinib(Sotyktu) | Approved | TYK2Small molecule | Psoriatic ArthritisPsoriasisSystemic Lupus ErythematosusSjögren's Disease |
| Approved | SLAMF7 (CS1/CD319)Monoclonal antibody | Multiple Myeloma | |
Enasidenib(Idhifa) | Approved | IDH2Small molecule | Acute Myeloid Leukemia |
| Approved | HBV polymerase (reverse transcriptase)Small molecule | Chronic Hepatitis B | |
Iberdomide(Zenbexus) | Approved | Cereblon E3 ubiquitin-ligaseSmall molecule | Multiple Myeloma |
| Approved | BCMACell therapy | Multiple Myeloma | |
| Approved | CTLA-4 antagonistMonoclonal antibody | Non-Small Cell Lung CancerHepatocellular CarcinomaColorectal CancerBladder / Urothelial CancerRenal Cell CarcinomaMelanomaEsophageal Cancer Urothelial Carcinoma, Metastatic Colorectal Cancer, Esophageal Squamous Cell Carcinoma, Cutaneous Melanoma, Advanced Metastatic Colorectal Cancer | |
| Approved | Cereblon E3 ubiquitin-ligase · Thalidomide AnalogSmall molecule | Multiple MyelomaFollicular LymphomaMyelodysplastic SyndromesMantle Cell Lymphoma | |
Mavacamten(Camzyos) | Approved | Cardiac myosin (inhibitor)Small molecule | Heart FailureHypertrophic Cardiomyopathy |
| Approved | MicrotubulesSmall molecule | Non-Small Cell Lung CancerBreast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Approved | PD-1Monoclonal antibody | Non-Small Cell Lung CancerHepatocellular CarcinomaColorectal CancerGastric CancerHead and Neck Squamous Cell CarcinomaBladder / Urothelial CancerRenal Cell CarcinomaMelanomaEsophageal Cancer Urothelial Carcinoma, Metastatic Colorectal Cancer, Esophageal Squamous Cell Carcinoma, Advanced Metastatic Colorectal Cancer |
Upcoming events
(145 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (22)
November 2026 (3)
December 2026 (19)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (36)
January 2027 (2)
February 2027 (2)
March 2027 (1)
What to watch
April 2027 (1)
What to watch
May 2027 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
June 2027 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
July 2027 (2)
What to watch
August 2027 (2)
September 2027 (2)
October 2027 (1)
What to watch
November 2027 (3)
2028 (36)
January 2028 (1)
February 2028 (3)
March 2028 (3)
April 2028 (1)
What to watch
May 2028 (1)
What to watch
June 2028 (1)
What to watch
July 2028 (2)
August 2028 (3)
September 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
October 2028 (3)
What to watch
What to watch
What to watch
November 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
December 2028 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (27)
January 2029 (5)
March 2029 (2)
April 2029 (2)
May 2029 (1)
What to watch
June 2029 (1)
What to watch
July 2029 (2)
What to watch
August 2029 (4)
What to watch
What to watch
What to watch
What to watch
October 2029 (2)
November 2029 (1)
What to watch
December 2029 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2030 (13)
February 2030 (1)
March 2030 (2)
April 2030 (1)
What to watch
May 2030 (1)
What to watch
June 2030 (1)
July 2030 (1)
What to watch
September 2030 (1)
October 2030 (1)
What to watch
November 2030 (1)
2031 (7)
January 2031 (1)
What to watch
February 2031 (1)
What to watch
April 2031 (1)
What to watch
August 2031 (2)
What to watch
October 2031 (1)
December 2031 (1)
What to watch
2032 (3)
2033 (1)
December 2033 (1)
What to watch
Regulatory and conference events
(27)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
The 12 most recent of 25 past events are shown.
Financial reports
Quarterly & interim (18)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $13.1B | $2.4B | $9.6B+ $3.0B short-term inv. | —$4.2B operating cash flow | report ↗ |
View 17 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $13.0B | $3.0B | $8.7B+ $2.3B short-term inv. | —$3.4B operating cash flow | report ↗ |
| 2026-Q1 | $11.5B | $2.6B | $9.6B+ $912M short-term inv. | —$1.1B operating cash flow | report ↗ |
| 2025-Q4 | $12.5B | $2.6B | $10.7B | — | report ↗ |
| 2025-Q3 | $12.2B | $2.5B | $16.5B+ $776M short-term inv. | —$6.3B operating cash flow | report ↗ |
| 2025-Q2 | $12.3B | $2.6B | $13.6B+ $1.0B short-term inv. | —$3.9B operating cash flow | report ↗ |
| 2025-Q1 | $11.2B | $2.3B | $11.8B+ $907M short-term inv. | —$2.0B operating cash flow | report ↗ |
| 2024-Q4 | $12.3B | $3.2B | $10.9B | — | report ↗ |
| 2024-Q3 | $11.9B | $2.4B | $8.1B+ $204M short-term inv. | —$5.6B operating cash flow | report ↗ |
| 2024-Q2 | $12.2B | $2.9B | $6.7B+ $360M short-term inv. | —$2.3B operating cash flow | report ↗ |
| 2024-Q1 | $11.9B | $2.7B | $9.3B+ $340M short-term inv. | $11.9B$2.8B operating cash flow | report ↗ |
| 2023-Q3 | $11.0B | $2.2B | $7.6B+ $171M short-term inv. | —$4.8B operating cash flow | report ↗ |
| 2023-Q2 | $11.2B | $2.3B | $8.4B+ $358M short-term inv. | —$1.9B operating cash flow | report ↗ |
| 2023-Q1 | $11.3B | $2.3B | $9.0B+ $274M short-term inv. | —$3.0B operating cash flow | report ↗ |
| 2022-Q3 | $11.2B | $2.4B | $8.0B+ $1.3B short-term inv. | —$3.7B operating cash flow | report ↗ |
| 2022-Q2 | $11.9B | $2.3B | $11.0B+ $2.5B short-term inv. | —$2.3B operating cash flow | report ↗ |
| 2022-Q1 | $11.6B | $2.3B | $12.6B+ $2.6B short-term inv. | —$3.8B operating cash flow | report ↗ |
| 2021-Q3 | $11.6B | $3.3B | $13.9B+ $2.1B short-term inv. | —$5.3B operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $48.2B | $10.0B | $10.7B+ $464M short-term inv. | —$14.2B operating cash flow | report ↗ |
Bristol Myers Squibb reported full-year 2025 revenue of $48,194M, relatively flat YoY on a reported basis (down 1% Ex-FX), and R&D spend of $9,951M, down 11% YoY on a GAAP basis. Cash and cash equivalents were $10,209M (cash, cash equivalents and marketable debt securities of $11,069M), while GAAP net income attributable to BMS was $7,054M versus a net loss of $8,948M in 2024.
Growth Portfolio revenues rose 17% to $26.4B, while Legacy Portfolio revenues declined 15% to $21.8B. For 2026, the company guided to revenues of $46.0B-$47.5B and non-GAAP diluted EPS of $6.05-$6.35, with Eliquis worldwide revenue growth expected at 10%-15%. Pipeline highlights included positive Phase 3 SCOUT-HCM data for Camzyos, FDA priority review for Opdivo in classical Hodgkin lymphoma, FDA and European Commission approvals for Breyanzi, and a decision to stop the Phase 3 Librexia ACS trial of milvexian; the company also announced a Microsoft collaboration on AI-based lung cancer early detection and raised its quarterly dividend to $0.63 per share.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $48.3B | $11.2B | $10.9B+ $513M short-term inv. | —$15.2B operating cash flow | report ↗ |
| 2023-FY | $45.0B | $9.3B | $12.3B+ $816M short-term inv. | —$13.9B operating cash flow | report ↗ |
| 2022-FY | $46.2B | $9.5B | $9.3B+ $130M short-term inv. | —$13.1B operating cash flow | report ↗ |
| 2021-FY | $46.4B | $11.4B | $14.3B+ $3.0B short-term inv. | —$16.2B operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 5 sales ($2.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-05 | Haller Julia A · director | Open-market sale | 3,800 | $63.31 | $241K | Form 4 |
| 2026-11-03 | Lenkowsky Adam · EVP, Chief Commercial Officer | Option exercise | 7,522 | — | — | Form 4 |
| 2026-11-03 | Lenkowsky Adam · EVP, Chief Commercial Officer | Tax withholding | 3,848 | $61.71 | $237K | Form 4 |
| 2026-11-03 | Lenkowsky Adam · EVP, Chief Commercial Officer | Option exercise (derivative) | 7,522 | — | — | Form 4 |
| 2026-11-01 | Meyers Gregory Scott · EVP, Chief Digital & Tech Off. | Option exercise | 6,281 | — | — | Form 4 |
| 2026-11-01 | Shanahan Karin · EVP, Chief Supply Chain & Ops | Option exercise | 6,281 | — | — | Form 4 |
| 2026-11-01 | BOERNER CHRISTOPHER S. · director, Chief Executive Officer | Option exercise | 2,964 | — | — | Form 4 |
| 2026-11-01 | Meyers Gregory Scott · EVP, Chief Digital & Tech Off. | Tax withholding | 2,665 | $62.48 | $167K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 2,496 reporting institutions held 1607.6M shares ($92.6B, 78.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 171,682,888 | $10.4B |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 132,320,240 | $8.0B |
| 3 | STATE STREET CORP | 98,564,914 | $6.0B |
| 4 | JPMORGAN CHASE & CO | 92,475,194 | $5.5B |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 61,115,373 | $3.7B |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 55,286,174 | $3.3B |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 46,230,155 | $2.8B |
| 8 | BANK OF AMERICA CORP /DE/ | 32,586,981 | $2.0B |
| 9 | AQR CAPITAL MANAGEMENT LLC | 29,631,105 | $1.8B |
| 10 | MORGAN STANLEY | 29,198,554 | $1.8B |
| 11 | AMERIPRISE FINANCIAL INC | 26,470,718 | $1.6B |
| 12 | PRIMECAP MANAGEMENT CO/CA/ | 24,985,149 | $1.5B |
| 13 | NORTHERN TRUST CORP | 24,758,771 | $1.5B |
| 14 | Bank of New York Mellon Corp | 23,301,337 | $1.4B |
| 15 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 22,719,320 | $1.4B |